Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That would be a better one to start than the nash, if we were to start another trial.
The company just doesn't have the bandwidth or resources to start and maintain multiple trials, it will cause these trials to be delayed. We can't even get 390 patients in CD-12
IMO we shouldn't be starting anymore trials for other indications until we have approval on at least 1. We have cancer and covid that we need to focus on, as have HIV that has yet to be approved. We need to be careful on how we allocate our funds. Although the 25m shares that management wants for compensation is worth $75m...
Are you hearing anything on the uplisting? I'm assuming we didn't get it.
Not lying, who's to say who is big? What kind of talks, was cytodyn trying to show them data, that's a talk. Only speculation what "in talks" means. We all would like it to be about a partnership or buy out... Did BP contact us, or did we reach out to BP. After this last CC with Naders talk about EUA I reread the PR and states requested, not applied, so that go me thinking, how did he request a mention on an email, a phone call? Was it formal, informal? Tricky words
That's why I'm saying they have to focus on enrolling CD-12 patients, not start new trials. This is a critical time for covid.
It will take a top notch management team to get it to the place of saving lives. Big money doesn't want cures and sure shots, then want medicine that works, but you need to keep on using it, so they make money. I very much believe BP forces are against us, but they don't have to work that hard with Nader captaining the ship. This is his baby, he is now too close, and too emotional. He's taken it to the 1 yard line, and now we need a stronger player to get it across the line. He's outlived his usefulness.
They NEED to focus on completing enrollment for CD12. We're just over 50% there 210 out of 390, chances are the DMSC will not halt the trial but will allow to continue. We shouldn't be starting other trails ie. NASH and "long haulers" until CD12 is complete.
If they are truly meant to attract new talent, then I'm all for it, there is a breakdown in the proxy information, Nader will stand to receive 5.5m shares, or $19.7m.
I just don't get it, clearly the tide has turned on Nader, especially with many of the longs, while they still support and believe in Leronlimab. So if you have Nader's ear or the ability to get it, why not step in and help him out now, he may not be around the end of the year. We have a vote on September 30th, tick tock.
Really?...
He should have pushed back on the FDA, when we completed the combo trial for 350mg. Then they asked for 700mg mono, which he just said on the CC the FDA will make us do a FULL phase 3 trial for mono, so that was a waste of time money and effort. We had something like 81% efficiency with 350mg, the next approved drug was 42% range. We should have been able to move forward with 350mg, then if the FDA wanted a 700mg mono we could start. DELAY DELAY DELAY and $$$$
Again,
Looking back at the proxy. The compensation package is roughly;
Nader 5.5m shares or $19.7m
Scott Kelly 1.75m shares or $6.125m
Mike Mulholland 400k shares or $1.4m
Nitya G. Ray, 850k shares or $2.975 (not sure what he does)
Arian Colachis 320k shares or $1.12m (for a lawyer?)
These funds could be used to get out equity positive, instead of lining their pockets.
Everyone has their chance to voice their opinion and either choose to vote him in or out. It is VERY important for people to vote. I think this last go around caused him to lose quite a bit of long support. No EUA, and that whole compensation lie. A month or so requests 100m shares, states 10-15% will be used on future funding if needed. A month later requests use of 25% for a comp bump, 5.5% of which will go to him, at todays prices is $19m...
Yes,
That is the case, but are you hearing anything else?
I would hope the company is accelerating enrollment, just in case. Per the last call we were at 210, which is just over 50% of what we need, add 28 days... Realistically we're looking at the end of the year if the trial continues.
Still on for the 23rd?
NP's comp package this year is $9.7m
If we got the same buyout $21b. Which would equate to roughly $30/share. Those shares would be worth $165m
Wow, $20m for Nader, just in stock.
What is this based on? Now you're just throwing out things to see if they stick. They haven't even tapped into the 100m that was just authorized.
There are several tiers to NASDAQ, $4/share being the easiest avenue. We have been holding strong at the 2nd tier $3/share, the only thing we're missing on this level as stated several times over several calls is positive equity, $4-5m. Currently I believe we are -$2m. Management has stated they will perform a small offering within 24-48 hours and then will satisfy that requirement. As stated, even if we were at $30/share ultimately it is up to NASDAQ to move forward or not. We meet, or can meet the requirements, it is now up to NASDAQ if they feel the path forward is justified.
Maybe they should announce their intentions publicly? I mentioned this before, for all we know the company has been getting offers, but are turned away, as management feels they should be considerably higher. I would like to know at what point an offer is brought to shareholders? Who determines that? If I made an offer to buy the company at $10/share right now, would that be turned down, would the share holders get to vote?
The only thing I can think of, is the company is setting up for a buyout. We have many phase 2 trials started/approved, HIV completed, Covid CD12 ready for intrim. Nader spent quite a bit of time talking about IMMU's purchase, and stated the buyout would need to be higher, why focus on another company at all during a company call? We had several doctors (unpaid) telling the world what they saw. And this compensation package. If it is to last the next 10 years, why do we need to approve so many shares right now? We now know LL crosses the blood brain barrier, which will be HUGE. This will be bigger than Humaria.
I too hope they decide not to move forward with phase 3 on m/m population. If we get the EUA for S/C I don't see why they can't use our phase 2 m/m to allow usage.
We were down as expected, but held pretty good. I expected a larger drop, I knew if we dipped below $3, it was just a dip and would close above $3. But we recovered quickly and held, never dipping below $3. Mullholland has been going back and forth with Nasdaq for a few weeks now, I hope they have ironed out any concerns and came up with a path forward. next 3-4 weeks should be interesting with possible uplist and CD12 results. Hopefully the company will share some prelim data from what they're seeing as an early indication.
At the end of the day, with all of the positives, and negatives. There are several factors that an investor should be focused on. 1, the FDA (whether you believe it is against us or not), has looked at all of the data Cytodyn has provided over the years, and had continuously advanced trials, and approved new trials, at anytime they could have said no, so they must seem something positive in Leronlimab. Secondly, all of our scientific board advisors, are well respected in their fields of medicine, and have no doubt analyzed the data prior to associating their name with this drug/company. I can not imagine anyone risking their reputation which took a lifetime to build, on something they didn't believe in, and know is real. The science will prevail!
Investment banking and research firm H.C. Wainwright said it would maintain a “neutral” rating after CytoDyn announced its Covid results in August, because it’s not clear the FDA will accept them. The firm gives CytoDyn an 85 percent probability of approval for its HIV indications and 50 percent for Covid.
As long as we continue to close above $2 there is a chance. At $3/share I believe the only thing missing is positive equity, which the company said they can do a small raise in 24-48 hours. That being said, on the CC, Nader said at the end of the day it's up to NASDAQ if they want us to be on or not, whether we're sitting at $3/share or $30/share.
What happened to your 9/23 event? Doesn't that make you still feel positive or is that finished now?
Well between your 23rd comment the other day, and the hint of is the price holds when asked about your confidence if the call would effect the news, I would say uplisting is what you were referring to.
Inquiring minds want to know what is the news? Anyone can say news will be out.
What kind of news, so you're saying the Wednesday after the call 9/23?
1985 to now is 35 years. That person who sold and bought a home, enjoyed memories. No guarantee you'll live to see the future, and if I was him, I sure wouldn't regret it.
Give me a buyout now for $30/share range, I won't retire, but I won't regret it either. I don't care if 10-20 years the price is $300-$3000/share
The number doesn't matter, what matters is you're more effective then the rest. Which we are.
The ONLY way I see this meeting as a success, is if the BLA PDUFA date is still on track, if we have to re-submit and wait another 6-10 months for a PDUFA date, then in NO way do I see that as a success. If we receive a PDUFA date for review by the end of the year, then yes, that is a great call. I'm assuming the FDA said they will accept mono as well, but we will need to re-submit further delaying approval into 2nd half of 2021.
The meeting for the BLA happened this past Monday. Why they haven't submit the BLA since, and it sounds like it won't be submitted until after the call is beyond me.
We get to talk about the BLA submission. JUST SUBMIT IT why are we waiting another week.
I suppose your outlook depends on how long you have been invested here. Some already have 5-10 years here, do they want to wait another 5-10? How long is someone suppose to hold?
That won't happen, Google
Top pharmaceutical deals, I think the highest was around $75b. That was for an established company.
I really hope that the team has something concrete on Wednesday. Again the PR states upcoming submission. WHY can't they just get something done first then state it has been submitted. Why are we having a call a week out to hear they will submit the BLA by the end of the week? Plus the "special guests" That is a nothing burger, we don't need to hear about the EIND patients, we've all heard about them. There is NO mention of uplisting on that PR. We can only hope that the BLA information is about the BLA date still being on track by EoY. If not I can't understand why you would host a call 2 weeks before a shareholder meeting and provide nothing. ESPECIALLY when we get to vote for management on the meeting, and your compensation.